Antithrombotic therapy after transcatheter aortic valve replacement

Area of Science:

• Cardiology
• Valvular Heart Disease
• Interventional Cardiology

Background:

• Aortic stenosis (AS) is a growing concern in aging populations, impacting patient prognosis.
• Transcatheter aortic valve replacement (TAVR) is a standard treatment for severe AS, with rising global utilization.
• Post-TAVR complications like ischemic and bleeding events necessitate effective antithrombotic strategies.

Purpose of the Study:

• To review the current landscape of antithrombotic therapy following TAVR.
• To discuss recent randomized control trials and their impact on treatment guidelines.
• To address the issue of leaflet thrombosis after TAVR.

Main Methods:

• Literature review of recent randomized control trials (RCTs) on antithrombotic therapy post-TAVR.
• Analysis of current guidelines and expert consensus on antithrombotic management.
• Examination of data on leaflet thrombosis and its prevention.

Main Results:

• Evidence from recent RCTs is rapidly evolving the optimal antithrombotic regimen post-TAVR.
• The balance between preventing thromboembolic events and minimizing bleeding risk remains a key challenge.
• Leaflet thrombosis is a recognized complication requiring further investigation and management strategies.

Conclusions:

• Optimal antithrombotic therapy after TAVR is a dynamic field influenced by new clinical evidence.
• Personalized antithrombotic strategies may be necessary to balance efficacy and safety.
• Further research is needed to clarify the best antithrombotic approaches and address leaflet thrombosis.